GeoVax Labs, Inc. (NASDAQ:GOVX) Receives $12.67 Consensus PT from Brokerages

GeoVax Labs, Inc. (NASDAQ:GOVX) has received a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $13.25.

A number of equities research analysts have recently issued reports on GOVX shares. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a research report on Monday, August 12th. Noble Financial lifted their price objective on GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a report on Monday, August 19th. Alliance Global Partners initiated coverage on GeoVax Labs in a report on Monday. They issued a “buy” rating and a $15.00 target price on the stock. Finally, EF Hutton Acquisition Co. I raised GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd.

GeoVax Labs Stock Down 16.9 %

Shares of GOVX stock opened at $2.70 on Monday. The business’s fifty day moving average price is $2.44 and its 200 day moving average price is $2.59. GeoVax Labs has a 1-year low of $1.09 and a 1-year high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The company had revenue of $2.79 million for the quarter, compared to analyst estimates of $1.84 million. During the same period last year, the company earned ($4.80) earnings per share. As a group, equities research analysts anticipate that GeoVax Labs will post -5.1 EPS for the current year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.